Opinion editor's note: Star Tribune Opinion publishes a mix of national and local commentaries online and in print each day. To contribute, click here.
•••
Last year, one of my constituents, Bob Miller, told me a story I will never forget.
Bob is a 71-year-old on Medicare who suffers from multiple sclerosis (MS), an unpredictable and debilitating disease that impacts his central nervous system. For over a decade, Bob relied on Betaseron to treat his MS flare-ups and prevent the disease from progressing.
But over the years, Bob watched the cost of this life-sustaining medicine skyrocket. By 2016, his out-of-pocket cost for Betaseron had risen to over $10,000 a year and Bob was forced to stop taking the drug he relied on to manage his MS. Even with insurance, this drug was too expensive.
While Bob's situation broke my heart, his story is not unfamiliar to me. We live in one of the richest countries in the world — and yet many Minnesotans are left wondering each month if they'll be able to refill the prescriptions they rely on every day. The fact that so many Minnesotans share this common struggle is unconscionable.
Earlier this month I was proud to play a role in making the Inflation Reduction Act a reality and ensuring that we are finally able to start tackling the cost of prescription drugs costs. Starting next year, no one on Medicare will pay more than $35 a month for their insulin, seniors on Medicare will be able to access their vaccines free-of-cost and drug companies will be required to reimburse taxpayers if the costs of their prescription drugs rise faster than inflation. For the first time in history, Medicare will have the power to negotiate fair drug prices for certain drugs on behalf of seniors like Bob.
This bill will lower out-of-pocket prescription drug prices for millions of Americans. That is significant progress — and finally asks Big Pharma to compete — something they already should have to do when vying to serve our nation's seniors.